UPDATE: Credit Suisse Initiates Abbott Laboratories with Neutral on Modest Upside Potential

In a report published Friday, Credit Suisse analyst Bruce Nudell initiated coverage on Abbott Laboratories (NYSE: ABT ) with a Neutral rating and $40.00 price target. In the report, Nudell noted, “While we forecast attractive ~7% and 11% sales & EPS growth, respectively, for ABT 2012-17, above that of comparable